Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
BOSTON, April 01, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human,...
-
Apollomics Inc. Announces $2.0 Million Bridge Financing
-
PDUFA target action date of November 14, 2026 Potential first FDA-approved treatment option for the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home...
-
BudPop earns top THCP gummy ranking in 2026 after independent reviewers tested 40+ brands on potency accuracy, lab verification, and ingredient quality.
-
SALT LAKE CITY, March 31, 2026 (GLOBE NEWSWIRE) -- INTERMOUNTAIN NEWS RELEASE Approximately 1 in 15 children in Utah will experience the death of a parent or sibling before the age of 18....
-
The study highlights expanding applications in water treatment, pharmaceuticals, and chemical processing as key drivers of global market growth.
-
Aptose Biosciences Announces Results of Special Shareholders Meeting; Announces Receipt of Final Court Approval of Plan of Arrangement; Reports Year End 20
-
TORONTO, March 31, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory...
-
Rinzimetostat 400 mg once daily selected as RP3D in combination with darolutamide for Himalayas-1 global Phase 3 registrational trial in post-abiraterone mCRPC, with initiation expected in 1H 2026 At...
-
Inhibitor Therapeutics (OTCQB: INTI) updates itraconazole PK study, highlights amorphous formulation and planned global patent filing.